Control Bionics (ASX: CBL) has achieved a significant milestone with its NeuroNode device securing a German statutory reimbursement listing, enabling broader market access and supporting its strategic pivot to a wholesale distribution model in Europe.
Control Bionics' NeuroNode device has been formally included in Germany's Hilfsmittelverzeichnis under §139 SGB V, a critical step for market access.
The device has been assigned Position Number 16.99.04.1013 (NeuroNode – PL-27-1000), validating its regulatory, safety, and quality standards, while making it eligible for reimbursement across Germany's statutory health insurance funds.
Wholesale Distribution Strategy Shift
The successful listing in Germany supports Control Bionics' pivot to a NeuroNode-only wholesale distribution model across Europe that aims to streamline market penetration and scale operations.
The company's immediate next steps involve appointing a German distributor, initiating pricing and contracting negotiations, and commencing pilot installations following these arrangements.
This formal reimbursement listing removes a significant commercial barrier for Control Bionics' entry into the German market.
It validates the device's compliance with local standards and facilitates access for patients covered by statutory health insurance funds.
The move also supports broader European market entry for NeuroNode, potentially improving the company's leverage in future distributor negotiations across the continent.
US Market Penetration & Funding
This European expansion follows Control Bionics' significant efforts in the US market, where sales have been driven by the HCPCS reimbursement code, which became effective on 1 October 2024.
The US market contributed 77.7% of the company's record A$6.1 million revenue in FY25.
Despite this revenue growth, Control Bionics posted a net loss of A$6.1 million in FY25 and held cash and cash equivalents of A$594,733 at year-end.
The company has relied on capital raises, including a net A$5.2 million raised in FY25, and debt financing, such as a A$450,000 loan at 12% interest secured by R&D tax refund, to fund its operations.
A rights issue was also announced to raise up to A$2.062 million post-year end.
Outlook and Risks
The German reimbursement listing is a positive catalyst for Control Bionics' European expansion and wholesale strategy.
However, successful execution relies heavily on the timely appointment of a suitable German distributor and effective pricing and contracting.
The company continues to face significant funding and market adoption risks, as evidenced by its ongoing losses and reliance on further capital raises to achieve cash flow positive performance.
Execution in new markets and partnerships also presents challenges and timing uncertainty.
